☆ 4.4 Letter

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient

KIDNEY RESEARCH AND CLINICAL PRACTICE (2022)

Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients

Aileen X. Wang et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

添加到收藏夹

Letter Surgery

Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants

Nicholas W. Lange et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

添加到收藏夹

Article Surgery

Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients

David M. Salerno et al.

Summary: The use of Nirmatrelvir/ritonavir (NR) in solid organ transplant recipients (SOTRs) with mild COVID-19 has not been described yet. The objective of this study was to evaluate outcomes among SOTRs and describe the drug-drug interaction of NR. The results show that the clinically significant interaction between NR and immunosuppressive agents can be reasonably managed with a standardized dosing protocol.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

添加到收藏夹

Article Immunology

Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report

Marios Prikis et al.

Summary: The COVID-19 pandemic has impacted communities and health systems significantly, and new antiviral medications have not been thoroughly tested. Drug interactions may affect the treatment outcomes of organ transplant recipients, emphasizing the importance of monitoring for adverse effects.

TRANSPLANTATION PROCEEDINGS (2022)

添加到收藏夹

Article Surgery

Two distinct cases with COVID-19 in kidney transplant recipients

Yaerim Kim et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2020)

添加到收藏夹

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient

相关参考文献

Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients

Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants

Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients

Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report

Two distinct cases with COVID-19 in kidney transplant recipients

导出引文

分享论文